TY - JOUR
T1 - The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma–Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses
AU - Maxwell, Russell
AU - Luksik, Andrew S.
AU - Garzon-Muvdi, Tomas
AU - Lim, Michael
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Purpose of Review: Malignant gliomas, including glioblastoma and anaplastic astrocytoma, are the most frequent primary brain tumors and present with many treatment challenges. In this review, we discuss the potential of cellular- and viral-based immunotherapies in the treatment of malignant glioma, specifically focusing on dendritic cell vaccines, adoptive cell therapy, and oncolytic viruses. Recent Findings: Diverse cellular- and viral-based strategies have been engineered and optimized to generate either a specific or broad antitumor immune response in malignant glioma. Due to their successes in the preclinical arena, many of these therapies have undergone phase I and II clinical testing. These early clinical trials have demonstrated the feasibility, safety, and efficacy of these immunotherapies. Summary: Dendritic cell vaccines, adoptive cell transfer, and oncolytic viruses may have a potential role in the treatment of malignant glioma. However, these modalities must be investigated in well-designed phase III trials to prove their efficacy.
AB - Purpose of Review: Malignant gliomas, including glioblastoma and anaplastic astrocytoma, are the most frequent primary brain tumors and present with many treatment challenges. In this review, we discuss the potential of cellular- and viral-based immunotherapies in the treatment of malignant glioma, specifically focusing on dendritic cell vaccines, adoptive cell therapy, and oncolytic viruses. Recent Findings: Diverse cellular- and viral-based strategies have been engineered and optimized to generate either a specific or broad antitumor immune response in malignant glioma. Due to their successes in the preclinical arena, many of these therapies have undergone phase I and II clinical testing. These early clinical trials have demonstrated the feasibility, safety, and efficacy of these immunotherapies. Summary: Dendritic cell vaccines, adoptive cell transfer, and oncolytic viruses may have a potential role in the treatment of malignant glioma. However, these modalities must be investigated in well-designed phase III trials to prove their efficacy.
KW - Adoptive cell transfer
KW - CAR T cells
KW - Dendritic cell vaccines
KW - Glioma
KW - Immunotherapy
KW - Oncolytic virus
UR - http://www.scopus.com/inward/record.url?scp=85019111579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019111579&partnerID=8YFLogxK
U2 - 10.1007/s11910-017-0754-x
DO - 10.1007/s11910-017-0754-x
M3 - Review article
C2 - 28488122
AN - SCOPUS:85019111579
SN - 1528-4042
VL - 17
JO - Current Neurology and Neuroscience Reports
JF - Current Neurology and Neuroscience Reports
IS - 6
M1 - 50
ER -